BI 3000202
Sponsors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim
Conditions
HealthyHepatic ImpairmentSystemic Lupus ErythematosusSystemic lupus erythematosus
Phase 1
A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood
CompletedNCT05945888
Start: 2023-07-25End: 2023-11-13Updated: 2026-06-08
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam
CompletedNCT06327256
Start: 2024-04-09End: 2024-09-27Updated: 2024-11-13
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
CompletedNCT07215260
Start: 2025-11-05End: 2025-12-18Updated: 2025-12-22
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body
CompletedNCT07273474
Start: 2025-12-30End: 2026-03-25Updated: 2026-03-31
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
RecruitingNCT07486102
Start: 2026-05-01End: 2027-02-27Target: 44Updated: 2026-05-14
A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood
RecruitingNCT07774325
Start: 2026-09-01End: 2026-10-26Target: 16Updated: 2026-09-09
Phase 2
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
RecruitingNCT07409181
Start: 2026-04-20End: 2029-07-08Target: 405Updated: 2026-09-17
Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)
Not yet recruitingCTIS2025-523488-39-00
Target: 7Updated: 2026-05-04